SELLAS Life Sciences Touts Encouraging Preclinical Data For Candidate For Aggressive Form Of Prostate Cancer
SELLAS Life Sciences Group Inc (NASDAQ: SLS) announced results from a new preclinical in vitro study for its highly selective…
Pieris Pharma Shares Pop On Preclinical Data From Potential Lung Disease Candidate
Pieris Pharmaceuticals Inc (NASDAQ:PIRS) announced the presentation of preclinical data for PRS-400, an inhaled Jagged-1 Anticalin protein for muco-obstructive lung diseases,…
Apellis Shares Show Mixed Reaction After Positive 2 Years Data From Late-Stage Retinal Disorder Study
Apellis Pharmaceuticals (NASDAQ: APLS) revealed top-line data readout at 24 months showing increased effects over time with intravitreal pegcetacoplan in the Phase 3 DERBY and OAKS studies in geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Ainos Seeks FDA Nod For Mid-Stage Covid-19 Study
Ainos, Inc. (NASDAQ: AIMD) has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for conducting a Phase 2 trial of its drug candidate VELDONA, for treatment of mild symptoms related to COVID-19.
BioCardia Enters Agreement with BlueRock Therapeutics To Provide Enabling Catheter Biotherapeutic Delivery Product Candidates For BlueRock’s Cell Therapy To Treat Heart Failure
BioCardia®, Inc. (NASDAQ:BCDA), today announced that it has entered into an agreement with BlueRock Therapeutics LP for the delivery of BlueRock's cell therapy product candidates for the treatment of
Recap Of Tuesday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Merck‘s (NYSE:MRK) lead asset MK-2060…
Boxed Warnings May Not Hinder This Depression Drug’s Broad Market Penetration, Analyst Says
Last week, Axsome Therapeutics Inc’s (NASDAQ:AXSM) major depression candidate received the much-awaited FDA approval. HC Wainwright notes that the approval comes roughly…
Mizuho Is Bullish On This Schizophrenia-Focused Stock, Read Why
Mizuho updated the price target for Cerevel Therapeutics Holdings Inc (NASDAQ:CERE) from $27 to $32 keeping the Neutral rating. The updated model…
Moderna Plans US Application Submission For COVID-19 Omicron Adapted Booster ‘Very Soon’
Moderna Inc (NASDAQ:MRNA) plans to file data with the FDA very soon, seeking approval for a booster shot targeting…
Sorrento Shares Pop After Interim Data From Lung Cancer Trial
Sorrento Therapeutics Inc (NASDAQ: SRNE) announced positive results from a pivotal study of Abivertinib on 209 response evaluable, heavily pretreated NSCLC patients by an IRC assessment with matured long-term follow-up data.